新诊断的多发性骨髓瘤,有出血和凝血异常,由血抑制物质引起
Fumiya Ohara1,2, Atsuo Suzuki3, Nobuaki Suzuki4
1Department of Hematology, National Center for Geriatrics and Gerontology, 7-430 Morioka-Cho, Obu, Aichi, 474-8511, Japan.
International journal of hematology
|September 18, 2024
概括
这份病例报告详细介绍了一名患有多发性骨髓瘤 (MM) 的患者,由于一种新型血栓抑制物质而出现出血. 用达拉图穆马布,莱纳利多米德和德克萨梅他治疗改善了凝血异常.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 内部医学 内部医学
背景情况:
- 多发性骨髓瘤 (MM) 在大约7%的新诊断患者中可能会出现出血并发症.
- 在MM中出血的具体原因和机制尚未完全阐明.
- 很少有病例报告描述了MM患者的出血并发症.
研究的目的:
- 报告一个新诊断的多发性骨髓瘤病例,呈现出出血倾向和凝血异常.
- 为了调查患者中发现的血栓激素抑制物质的性质.
- 描述治疗结果和从这个案例中获得的见解.
主要方法:
- 一个新确诊的多发性骨髓瘤患者的病例报告.
- 凝血评估包括染色体检测,血栓时间和爬行动物酶时间.
- 在治疗期间监测凝血异常.
主要成果:
- 患者呈现出出血倾向和各种凝血异常.
- 鉴定出一种抑制血栓激素的物质,抑制纤维素A从纤维素原释放.
- 在用达拉图穆马布,莱纳利多米德和德克萨米他治疗后,凝血异常得到改善.
结论:
- 这一案例凸显了多发性骨髓瘤中出血并发症的罕见原因.
- 血抑制机制需要进一步研究.
- 在这种情况下,用达拉图穆马布,莱纳利多米德和德克萨梅他治疗显示出有效管理凝血异常.
相关概念视频
Disorders of Hemostasis
739
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
739
Anticoagulant Drugs: Low-Molecular-Weight Heparins
649
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
649
Extrinsic and Intrinsic Pathways of Hemostasis
6.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.4K
Coagulation
5.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
5.5K


